Arrowhead Pharmaceuticals, Inc.
ARWRArrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
Drugs in Pipeline
20
Phase 3 Programs
3
Upcoming Catalysts
5
Next Catalyst
This month
Market Overview
Stock performance and key metrics
5 upcoming, 2 past
ARO-DIMERPA Phase 2 Est. Readout
Primary completion for ARO-DIMERPA trial (NCT07223658) in Hyperlipidemia; Mixed
SourcePlozasiran Injection Phase 3 Est. Readout
Primary completion for Plozasiran Injection trial (NCT06347016) in Severe Hypertriglyceridemia
Source3 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Plozasiran Injection
Severe Hypertriglyceridemia
zodasiran Injection
Homozygous Familial Hypercholesterolemia
Plozasiran
Familial Chylomicronemia
ARO-MMP7 Inhalation Solution
Idiopathic Pulmonary Fibrosis
ARO-APOC3
Mixed Dyslipidemia
ARO-MAPT-SC
Alzheimer Disease
ARO-INHBE
Obesity
ARO-HSD Injection
Non-alcoholic Steatohepatitis
ARO-AAT
Alpha 1-Antitrypsin Deficiency
ARO-C3
C3 Glomerulopathy
ARO-ALK7
Obesity
ARO-HBV
Hepatitis B
ARO-RAGE
Asthma
Fazisiran Injection
Alpha 1-Antitrypsin Deficiency
ARO-ANG3
Mixed Dyslipidemia
ARO-ANG 3 Injection
Homozygous Familial Hypercholesterolemia
ARO-DIMERPA
Hyperlipidemia; Mixed
ARO-DUX4 for Injection
Facio-Scapulo-Humeral Dystrophy
ARO-DM1 Intravenous (IV) Infusion
Myotonic Dystrophy 1
ARO-CFB
IgA Nephropathy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Plozasiran Injection | Phase 3 | Severe Hypertriglyceridemia | - | - |
zodasiran Injection | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Plozasiran | Phase 3 | Familial Chylomicronemia | - | - |
ARO-MMP7 Inhalation Solution | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
ARO-APOC3 | Phase 2 | Mixed Dyslipidemia | - | - |
ARO-MAPT-SC | Phase 2 | Alzheimer Disease | - | - |
ARO-INHBE | Phase 2 | Obesity | - | - |
ARO-HSD Injection | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
ARO-AAT | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
ARO-C3 | Phase 2 | C3 Glomerulopathy | - | - |
ARO-ALK7 | Phase 2 | Obesity | - | - |
ARO-HBV | Phase 2 | Hepatitis B | - | - |
ARO-RAGE | Phase 2 | Asthma | - | - |
Fazisiran Injection | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
ARO-ANG3 | Phase 2 | Mixed Dyslipidemia | - | - |
ARO-ANG 3 Injection | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
ARO-DIMERPA | Phase 2 | Hyperlipidemia; Mixed | - | - |
ARO-DUX4 for Injection | Phase 2 | Facio-Scapulo-Humeral Dystrophy | - | - |
ARO-DM1 Intravenous (IV) Infusion | Phase 2 | Myotonic Dystrophy 1 | - | - |
ARO-CFB | Phase 2 | IgA Nephropathy | - | - |